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ABSTRACT HIV proteinase inhibitors reduce the
levels of Leishmania parasites in vivo and in vitro, but
their biochemical target is unknown. We have identified
an ortholog of the yeast Ddi1 protein as the only
member of the aspartic proteinase family in Leishmania
parasites, and in this study we investigate this protein as
a potential target for the drugs. To date, no enzyme
assay has been developed for the Ddi1 proteins, but
Saccharomyces cerevisiae lacking the DDI1 gene secrete
high levels of protein into the medium. We developed
an assay in which these knockout yeast were function-
ally complemented to low secretion by introduction of
genes encoding Ddi1 orthologs from Leishmania major
or humans. Plasmid alone controls gave no complemen-
tation. Treatment of the Ddi1 transformants with HIV
proteinase inhibitors showed differential effects de-
pendent on the origin of the Ddi1. Dose responses
allowed calculation of IC50 values; e.g., for nelfinavir,
of 3.4 M (human Ddi1) and 0.44 M (Leishmania
Ddi1). IC50 values with Leishmania constructs mirror
the potency of inhibitors against parasites. Our results
show that Ddi1 proteins are targets of HIV proteinase
inhibitors and indicates the Leishmania Ddi1 as the
likely target for these drugs and a potential target for
antiparasitic therapy.—White, R. E., Powell, D. J.,
Berry, C. HIV proteinase inhibitors target the Ddi1-
Like protein of Leishmania parasites. FASEB J. 25,
1729–1736 (2011). www.fasebj.org
Key Words: proteasome  HAART
A growing literature has emerged recently that
shows the effects of HIV proteinase inhibitors (HIVPrIs),
at therapeutically relevant doses, on other potential
pathogens. Effects have been reported against Plasmo-
dium species, (1–10), Candida (11–14), Leishmania spe-
cies (15–17), and a range of other opportunistic infec-
tions (18). In HIV therapy, the inhibitors act against the
retroviral aspartic proteinase, a homodimeric viral en-
zyme of the A2 proteinase family (19), with low nano-
molar or subnanomolar Ki values (20). Therapeutic
doses might reach plasma concentrations in the tens of
micromolar range (4) that are sufficient to inhibit
known monomeric (A1 family) aspartic proteinases
from Candida albicans (11–13) and Plasmodium species
(6, 7, 21). In Plasmodium, only food vacuole aspartic
proteinases have been tested for susceptibility, al-
though 10 members of the A1 proteinases (plas-
mepsins) are present in Plasmodium falciparum (22).
HIVPrIs appear to act on erythrocytic stage parasites
and pre-erythrocytic stages (1), and the production of
food vacuole plasmepsins by the latter has not been
established. However, HIVPrI have different effects on
parasites from the general aspartic proteinase inhibitor
pepstatin and are equally effective against food vacuole
plasmepsin knockouts (3), implying another target for
these drugs, as suggested by other investigators (8).
HIVPrI interact antagonistically with artemisinin and
related compounds (23) but synergistically with chloro-
quine (8, 24, 25). The latter interactions might be
mediated via glutathione metabolism (24). Other in-
hibitor effects have been reported, including changes
in CD36-mediated cytoadherence that cause a reduc-
tion in macrophage phagocytosis of parasite-infected
erythrocytes (5). From these observations, it is clear
that the exact mechanism and actual parasite proteins
that are inhibited by the HIVPrI therapy remain to be
confirmed. Of particular interest in the context of
parasite aspartic proteinases as possible targets for the
HIVPrIs are the effects on Leishmania species. Aspartic
proteinase activity has been reported in extracts from
these parasites (26, 27) but inspection of the completed
genomes of Leishmania species reveals that these para-
sites do not encode A1 family, monomeric aspartic
proteinases. The only aspartic proteinase present in
these parasites seems to be an A2 family, retroviral-like
proteinase that is related to the yeast Ddi1 protein and
is part of a family of proteins conserved throughout the
eukaryotes (28). Clearly, as the only representative of
the aspartic proteinases in Leishmania, particularly as a
retroviral-like enzyme, this protein is a potential target
for the HIVPrIs in these parasites.
The Ddi1 protein of the yeast Saccharomyces cerevisiae is
involved in a wide range of functions, including protein
targeting to the proteasome, control of cell cycle, and
suppression of protein secretion from the cell (29). Ddi1
has several distinct regions: an N-terminal ubiquitin-like
domain (UBL), the central retroviral-type aspartic protei-
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nase (RVP domain), and a C-terminal region containing a
t-SNARE binding region and a ubiquitin associated
(UBA) domain. In the Leishmania major ortholog (acces-
sion number XP_001687454), while the RVP domain is
well conserved, there is only a short (40 residue) exten-
sion at the N terminus and an 80 residue C-terminal
region that shows no similarity to that of the yeast Ddi1. In
this family of proteins, the RVP domain is best conserved
across the Eukaryotes, with major differences in the
flanking regions in different taxonomic groups. The
human ortholog is predicted to have an N-terminal UBL
domain (although with little identity to that of Ddi1) but,
like the Leishmania ortholog, lacks the C-terminal UBA
(30) and t-SNARE binding domains and has instead a
short (30 residue) region following the RVP that is
conserved in mammalian Ddi1 orthologs but with no
known function.
In this study, we demonstrate that both the human
and Leishmania Ddi1 orthologs can complement the
protein secretion phenotype of a yeast DDI1 knockout,
and we show the effects of a number of HIVPrI on both
enzymes. This work suggests that inhibition of the
Leishmania Ddi1 ortholog might be the mechanism by
which HIVPrI therapy mediates its antiparasitic action.
MATERIALS AND METHODS
Strains and plasmids
S. cerevisiae strains used in this study were BY4742 (Mat;
his3D1; leu2D0; lys2D0; ura3D0) and the DDI1-knockout
derivative Y16141 (BY4742; Mat; his3D1; leu2D0; lys2D0;
ura3D0; YER143w::kanMX4; hereafter referred to as DDI1
knockout) and were supplied by EUROSCARF (Frankfurt,
Germany).
S. cerevisiae strains were cultured using YEPD medium (10
mg/ml yeast extract, 20 mg/ml glucose, 20 mg/ml bactopep-
tone, 0.1 mg/ml uracil, and 0.1 mg/ml adenine) or selective
minimal medium (1.6 mg/ml yeast nitrogen base that does
not contain ammonium chloride or amino acids, 20 mg/ml
glucose, 5 mg/ml ammonium chloride, 20 g/ml histidine,
20 g/ml lysine, and 20 g/ml uracil).
Ddi1 constructs
The construct encoding the full-length Ddi1 from S. cerevi-
siae has been described previously (31). The equivalent
constructs encoding the human and Leishmania orthologs
were produced as follows. The full-length human gene was
amplified from a human cDNA library by PCR using EasyA
DNA polymerase (Stratagene, La Jolla, CA, USA) and
forward (CCATGGATGCTGATCACCGTGTACTGC) and
reverse (GGATCCTTAATGTTCTTTTCGTCCTGAATC)
primers, which contained NcoI or BamHI sites at their
respective 5 ends. The conditions used were 95°C for 5
min followed by 30 cycles of 95°C for 1 min, 60°C for 1 min,
and 72°C for 1 min, prior to a final elongation step of 72°C
for 5 min. The gene encoding the full-length L. major Ddi1
ortholog was amplified from L. major friedlin strain
genomic DNA in the same way using forward (CCATG-
GATGGACGAGCGCCAGCTAG) and reverse (GGATCCT-
TACGTGTCGAAGAGGAGCG) primers, which also con-
tained NcoI or BamHI sites at their respective 5 ends. The
resultant PCR products were ligated into the pGEM-T
vector (Promega, Southampton, UK) and sequenced. The
DNA inserts were excised with NcoI and BamHI and cloned
into yeast expression vector pVTL260 (32). The pVTL260
constructs were then transformed into the S. cerevisiae
DDI1-knockout strain Y16141 (a BY4742 derivative) by the
lithium acetate transformation method (33). Point muta-
tion of the L. major active site aspartate to alanine was
performed by PCR using the QuickChange Site-Directed
mutagenesis kit (Stratagene) using the forward and reverse
primers AAAGCCTTCGTCGCGTCCGGCGCGCAG and
CTGCGCCGGACGCGACGAAGGCTTTC.
Proteinase inhibitors
Proteinase inhibitors were obtained from a number of
sources, and their structures are shown in Fig. 1. The HIVPrIs
lopinavir, indinavir, and tipranavir were purchased from
Toronto Research Chemicals (Ontario, ON, Canada). Ritona-
vir was obtained from MoleKula UK Ltd. (Dorset, UK).
Nelfinavir was obtained from Pfizer Inc. (New York, NY,
USA), and saquinavir was received from Roche Products Ltd.
(Welwyn Garden City, UK). Amprenavir was provided by
GlaxoSmithKline (Harlow, UK). The general aspartic protei-
nase inhibitor isovaleryl pepstatin was purchased from Sigma-
Aldrich Chemicals (Poole, UK).
Proteinase inhibitor assay
Selective minimal medium (1.5 ml in a 24-well plate) was
inoculated with a colony from a selective minimal plate,
grown overnight at 30°C. The plates were incubated with
shaking in a Microtherm plate shaker incubator (Camlab,
Cambridge, UK), for 48 h at 30°C to an attenuance at 600 nm
of 2 in the presence or absence of inhibitor. After this time,
1 ml of culture was removed into a preweighed tube, and the
supernatant was separated from whole cells by centrifugation
at 13,000 rpm for 5 min. The supernatant was removed, and
the protein content was determined using the RC DC protein
assay kit (Bio-Rad, Hemel Hempstead, UK) with BSA as the
standard. The cell pellet was dried at 100°C and weighed so
that the secreted protein concentrations determined could
be normalized by expressing the protein concentration as
milligrams of protein secreted per milligram of dry weight.
Each experiment was repeated several times (as shown in the
figure legends), and values for the means  se were calcu-
lated. IC50 values were calculated from dose response titra-
tions with IC50s generated with the GraFit 5.1 data analysis
package (Erithacus Software Ltd., Surrey, UK). Inhibition of
protein secretion by compound was determined using a
4-parameter logistic fit with Eq. 1:
y 
a
1  x/IC50 s
 B (1)
where a is the fitted uninhibited value minus the background,
x is the inhibitor concentration, s is the Hill slope factor, and
B is the value of a noninhibited control sample.
Yeast cell morphology
Yeast cells were grown for 24 h at 30°C in selective minimal
medium, either in the presence or absence of 25 M inhibi-
tors, and their morphology was examined using a Leitz
Diaplan phase contrast microscope at 100 magnification
(Leica Microsystems, Wetzlar, Germany). Images were cap-
tured using a ProgRes C5 digital camera (Jenoptik, Jena,
Germany).
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RESULTS
We have confirmed previously an earlier report (34)
that DDI1-knockout yeast show significantly higher lev-
els of protein secretion than the wild-type parent and
that lower levels of secretion are restored by comple-
mentation with the DDI1 gene on plasmid pVTL260
(31). In this study, we cloned the genes encoding the
full-length Leishmania and human orthologs of Ddi1
into the same plasmid. Figure 2 shows that these
constructs also can restore secretion to wild-type, low
levels. Plasmid pVTL260 alone does not produce any
effect. A mutant of the Leishmania protein, in which the
putative active site aspartic acid residue (D58, function-
ally equivalent to D220 in S. cerevisiae Ddi1) was
changed to an alanine, was incapable of reverting yeast
to the low-secretion phenotype. This indicates that
catalytic activity is likely to be important for this phe-
nomenon (as we have previously demonstrated with S.
cerevisiae Ddi1; ref. 31).
We next investigated the ability of aspartic proteinase
inhibitors (25 M) to affect protein secretion, since
these compounds might also inhibit the catalytic activ-
ity of the Ddi1-like proteins. The general aspartic
proteinase inhibitor isovaleryl pepstatin was tested
along with 7 HIVPrIs against wild-type BY4742 yeast and
the Y16141-knockout yeast cells complemented with S.
cerevisiae Ddi1, the human ortholog, or the Leishmania
protein (Table 1 and Fig. 3). Several inhibitors pro-
duced high levels of secretion in the complemented
yeast, clearly blocking the complementation by the
Ddi1-like proteins. It should be noted that the level of
the effect and the apparent relative potencies of indi-
vidual inhibitors varies among the different constructs,
thus indicating that the Ddi1-like proteins, rather than
background factors in the yeast strain (including nu-
merous yeast A1 family aspartic proteinases), are the
targets of the inhibitors.
For those inhibitors that gave knockout levels of
secretion in the complemented strains, we assayed the
effects over a range of concentrations in order to
establish IC50 values for their activities. An example of
such a titration for nelfinavir against the Leishmania
complemented yeast is shown in Fig. 4, and the calcu-
Figure 1. Structures of inhibitors.
Figure 2. Protein secretion by yeast strains. Levels of protein
secretion per milligram dry weight of cells is shown for strain
BY4742 (n	24), DDI1-knockout strain Y16141 (n	24), and
strain Y16141 transformed with plasmid alone (pVTL260;
n	15) or the constructs encoding Ddi1 orthologs from S.
cerevisiae (Sc Ddi1; n	24), human (H Ddi1; n	6), L. major
(Lm Ddi1; n	26), and the active site mutant of the L. major
protein (Lm Ddi1 D58A; n	20). Bars represent means  se.
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lated IC50 values are shown in Table 1. Again, the
differential activity of these inhibitors against the dif-
ferent target enzymes is evident.
In the course of these experiments, we also observed
the yeast cultures microscopically. In cultures of DDI1-
knockout yeast transformed with plasmid alone or
plasmid encoding either the S. cerevisiae, Leishmania, or
human Ddi1 orthologs, cell size showed little variation
from that seen with the wild-type yeast (Fig. 5A–D,
shown for Leishmania and human compared to wild-
type and plasmid only). However, in cultures of con-
structs encoding the active site mutants of the Saccharomy-
ces or Leishmania proteins, cells with greatly enlarged
morphologies can be observed (80 and 80 – 85% of
cells, respectively), and cells appear to have a ten-
dency to clump together (Fig. 5E, F). Similar effects
were seen when constructs expressing the equivalent
nonmutant proteins were treated with concentra-
tions of HIVPrIs expected to abolish their catalytic
activity [e.g., 25 M amprenavir (Saccharomyces; 75%
of cells) and either amprenavir or nelfinavir (Leish-
mania; 85–90 and 95% of cells, respectively), as
shown in Fig. 5G–I]. These inhibitors showed no
effects on knockout yeast transformed with plasmid
alone or on yeast transformed to express the human
ortholog of Ddi1 (Fig. 5J–L).
DISCUSSION
Here we show that the human and L. major Ddi1
orthologs can complement the secretion phenotype of
the DDI1-knockout yeast strain Y16141, to restore wild-
type, low secretion levels. Previously, we have shown
that for complementation by S. cerevisiae Ddi1 itself,
both the putative active site aspartate residue (and thus
the proposed catalytic activity) and the N-terminal 179
aa contribute to the low-secretion phenotype and that
both are required for full complementation (31). The
full complementation by the human ortholog is consis-
tent with these previous results, since it possesses an
N-terminal UBL domain and the RVP. However, the
full complementation by the Leishmania protein, which
lacks the features of the Ddi1 N terminus and has only
TABLE 1. Percentage inhibition and IC50 values for wild-type S. cerevisiae and yeast complemented with Ddi1 family proteins
Y16141 Ddi1 Y16141 human Y16141 Leishmania
Inhibitor
BY4742, inhibition
at 25 M (%)
Inhibition at
25 M (%) IC50 (M)
Inhibition at
25 M (%) IC50 (M)
Inhibition at
25 M (%) IC50 (M)
Amprenavir 91 95 2.8  0.2 9 
 100 5.7  0.7
Indinavir 36 24 
 38 
 100 3.0  0.2
Isovaleryl
pepstatin 7 8 
 14 
 100 14  3
Lopinavir 6 6 
 0 
 38 56  4
Nelfinavir 50 40 
 97 3.4  0.4 100 0.44  0.03
Ritonavir 1 0 
 3 
 22 380  140
Saquinavir 31 24 
 18 
 100 2.8  0.3
Tipranavir 58 86 
 90 1.5  0.2 97 2.9  0.2
Results for the wild-type strain BY4742 are shown along with the DDI1-knockout strain Y16141 complemented with the Ddi1 homologs from
S. cerevisiae (Ddi1), human, or L. major. IC50 values are given as means  se (n	6).
Figure 3. Effect of proteinase inhibitors on secretion. Proteinase inhibitors (25 M) were assayed against Y16141 cells expressing
Ddi1 orthologs from S. cerevisiae (A), L. major (B), and human (C). Knockout strain Y16141 and the strain complemented with
the Ddi1 ortholog from each species are shown in the absence of inhibitors as the first two bars in each graph. Bars represent
means  se; n 	 6 for all inhibitors. Ampren, amprenavir; Indin, indinavir; Lopin, lopinavir; Nelfin, nelfinavir; IVP, isovaleryl
pepstatin; Riton, ritonavir; Saquin, saquinavir; Tipran, tipranavir.
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an 40-aa sequence upstream of the RVP, is, perhaps,
surprising. At this point, we can only speculate that
other factors in the Leishmania protein permit this full
complementation in the absence of the Ddi1-like N-ter-
minal residues.
A mutant of the putative active site aspartic acid
residue in the L. major Ddi1-like protein abolishes
complementation and produces a high-secretion phe-
notype. The yeast cells expressing Saccharomyces or
Leishmania active site mutants of the Ddi1 proteins also
contain cells that differ in their morphology from
wild-type yeast, DDI1-knockout yeast, and cells comple-
mented with nonmutant Ddi1 orthologs. When the
putative proteolytic activity is abolished by inhibition,
rather than by mutation, a similar effect is observed
with enlarged cells that appear to show a defect in
septation and/or cytokinesis (Fig. 5). Thus, either the
absence of Ddi1-like protein or the presence of or-
thologs likely to be active catalytically give a normal
morphology, whereas the presence of catalytically inac-
tivated Saccharomyces or Leishmania proteins can give
rise to the abnormal morphology. At this point, we can
only speculate on this phenomenon, but perhaps the
enlarged phenotype results from an important interac-
tion that is initiated in these cases, but which cannot
proceed normally due to the lack of catalysis. Enlarged
cells might be a result of a block in cell division, and
yeast Ddi1 is known to have a role in cell-cycle control
through UBL-mediated associations with the protea-
some (35–38), but the lack of such UBL domains on
the Leishmania protein makes this an unlikely factor
here. However, in another study, mutations in the
active site of yeast Ddi1 were implicated in checkpoint
regulation (29). In addition, overexpression of the S.
cerevisiae Ddi1 protein in yeast with a temperature-
sensitive mutation in the Sec9 t-SNARE has been re-
ported to result in the accumulation of low-density
secretory vesicles (34). We cannot currently assess the
relevance of this finding for our observations, but our
enlarged cells continue to secrete proteins into the
medium at a high rate (Figs. 2 and 3B) despite their
swollen appearance. Morphological changes in Leishma-
nia amazonensis parasites treated in culture with nelfi-
navir have been observed by transmission electron
microscopy and exhibited cytoplasmic shrinking and
an increase in the number of vesicles (17), which might
show some parallels with the yeast morphology ob-
served here. In addition, the effects of inhibitors on
cellular proliferation (17), and indications that antipro-
liferative effects on promastigotes and axenic amasti-
goes might be due to a blockage in cell division (39) are
consistent with their action on a Ddi1-like target.
However the complementation occurs, the Leishma-
nia protein restores wild-type secretion levels to DDI1-
knockout yeast, and this effect can be blocked by both
the general aspartic proteinase inhibitor isovaleryl pep-
statin and by HIVPrIs. To make a detailed assessment of
the interactions of HIVPrIs with the Ddi1 family pro-
teins, it would be desirable to assay the effects kineti-
cally using purified target proteins. However, extensive
attempts to establish such a kinetic assay using recom-
binant proteins have, thus far, proved unsuccessful. As
a result, our indirect assay using the yeast secretion
phenotype is currently the best-available test of inhibi-
tor action against these proteins.
The inhibitory potencies, as shown in Table 1, show
a general correlation with reported growth inhibition
by HIVPrIs in L. major (IC50: saquinavir, 7 M; indina-
vir, 8 M; ref. 15) and, to a lesser extent, the effects on
inhibition of cellular growth and multiplication with L.
amazonensis (IC50; nelfinavir, 15 M; lopinavir, 16 M;
amprenavir, 62 M; ref. 17). Leishmania infantum has
been reported to be relatively resistant to the action of
HIVPrIs compared to L. major (17), but sensitivity of L.
infantum and Leishmania donovani to nelfinavir in the
tens of micromolar range has also been reported (16).
Variations in the Ddi1-like proteins in the individual
Leishmania species might produce corresponding dif-
ferences in inhibitory sensitivity, but this condition is
hard to assess. No sequence exists for the L. amazonensis
protein, but the L. infantum Ddi1 ortholog differs from
that of L. major by 11 residues, 3 of which lie in the RVP
domain, while the Leishmania mexicana variant shows 19
changes compared to L. major (6 within the RVP
domain), and the protein from Leishmania braziliensis is
significantly longer at the N terminus and contains a
number of short insertions relative to the other Leish-
mania proteins. Further work will be required to assess
whether the differences in sequence are sufficient to
explain any differences the inhibitor sensitivity of the
parasites or whether other factors, for instance cellular
uptake, might be involved.
Such considerations are also important in comparing
previous experiments with parasites in culture (15, 17)
Figure 4. IC50 determination for nelfinavir against Y16141
expressing the L. major Ddi1 ortholog. Different concentra-
tions of inhibitor were added, and protein secretion was
measured as before. For each concentration, the assay was
repeated 6 times. Bars represent means  se. Using Eq. 1, the
IC50 was calculated as 0.44  0.03, Hill slope factor 0.72 
0.04.
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Figure 5. Morphology of yeast cells. Cells were grown in the presence or absence of amprenavir or nelfinavir (25 M).
A) Wild-type BY4742 cells. B–L) Y16141 cells transformed with pVTL260 plasmid (B), the L. major construct (C), the human
construct (D), the Saccharomyces active site mutant D220A construct (E), the L. major active site mutant D58A construct (F), the
Saccharomyces Ddi1 construct in the presence of 25 M amprenavir (G), the Leishmania construct in the presence of 25 M amprenavir
(H), the Leishmania construct in the presence of 25 M nelfinavir (I), pVTL260 plasmid in the presence of 25 M amprenavir
(J), pVTL260 plasmid in the presence of 25M nelfinavir (K), and the human construct in the presence of 25M nelfinavir (L). Scale
bars 	 20 M.
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with our experimental protocol using yeast transfor-
mants to assess inhibition of the individual target
proteins that they express. The yeast cell wall will
possess different compound permeability properties to
the native Leishmania cell membrane, and Saccharomyces
species also possess a range of ABC drug transporters in
their cell membranes (40), which might result in
intracellular exposure of the Ddi1 orthologs to concen-
trations of inhibitor that differ from those added to the
yeast medium.
Given the caveats related to inhibitor uptake in our
yeast system, the most potent inhibitors against the
Leishmania protein appeared to be nelfinavir, followed
by saquinavir, tipranavir, indinavir, and amprenavir
(Table 1). Against the human protein, tipranavir ap-
pears the most potent, followed by nelfinavir, while S.
cerevisiae Ddi1 is most susceptible to amprenavir. Thus,
our results indicate a better therapeutic window for the
Leishmania protein compared to the human ortholog
for inhibitors such as saquinavir, indinavir, and ampre-
navir. Previous studies have indicated direct effects of
HIVPrIs on the proteasome and its proteolytic activities
(41–43). In our yeast assay system, the yeast protea-
some, along with yeast pepsin family aspartic protein-
ases, are constant factors, so differential sensitivity
indicates activity of the HIVPrIs against the Ddi1-like
proteins. Our work would, therefore, indicate the pos-
sibility of a double action for HIVPrIs both on the
proteasome directly (as previously reported) and on
the Ddi1-like proteins that interact with the protea-
some (29).
The HIVPrIs are well-established therapeutics that
have undergone extensive biochemical, toxicity, and
clinical testing that constitute major expenses in the
development of new drugs. The extension of their use
to new neglected disease targets, such as leishmaniasis,
requires an understanding of their biochemical targets
in the parasites. Our results show that the Leishmania
Ddi1-like protein is susceptible to the action of HIVPrIs
and leads us to propose this protein as a target of
HIVPrIs in the parasites themselves. This proposition is
based on the inhibition data presented here and on our
bioinformatic analysis that confirms this protein as the
only aspartic proteinase encoded by the L. major ge-
nome. By extension, since the RVP domain found in
this protein is highly conserved throughout the eu-
karyotes (28), we would further suggest that the equiv-
alent proteins from Plasmodium and Candida albicans
are also possible targets for the HIVPrIs in these
pathogens. Here we have highlighted the importance
of these potential targets, established a simple inhibitor
screening protocol and produced a human counter-
screen using the human ortholog, that will be useful for
assessment of further inhibitors that might be devel-
oped to target the parasite enzymes.
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